This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Aging/ Geriatrics  • Lipids and Lipid Disorders  • Nutritional and Metabolic Disorders, Other  • Public Health, Other  • Screening  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy, Other  • Alert me on articles by topic

Observations From the Dallas Heart Study

Raphael See, MD; Jason B. Lindsey, MD; Mahesh J. Patel, MD; Colby R. Ayers, MS; Amit Khera, MD, MSc; Darren K. McGuire, MD, MHSc; Scott M. Grundy, MD, PhD; James A. de Lemos, MD

Arch Intern Med. 2008;168(10):1055-1062.

Background  The Screening for Heart Attack Prevention and Education (SHAPE) Task Force recommends noninvasive atherosclerosis imaging of all asymptomatic men (aged 45-75 years) and women (aged 55-75 years), except those at very low risk, to augment conventional cardiovascular risk assessment algorithms.

Methods  Among 2611 participants in the Dallas Heart Study aged 30 to 65 years who underwent computed tomography to measure coronary artery calcification, low-density lipoprotein cholesterol (LDL-C) therapeutic targets were calculated using both National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and SHAPE algorithms. The proportion of subjects reclassified as being "at goal" for LDL-C vs "not at goal" after implementation of the SHAPE recommendations was determined.

Results  More subjects were identified with LDL-C levels greater than or equal to goal based on SHAPE than on NCEP-ATP III (27.4% vs 21.6%), with 7.0% of individuals reclassified as having unmet LDL-C goals and 1.1% of individuals reclassified as at goal. When more aggressive optional LDL-C goals were implemented, 31.7% had LDL-C levels greater than or equal to goal using SHAPE recommendations vs 28.1% using NCEP-ATP III recommendations, with 6.3% of subjects reclassified as being not at goal and 2.7% as being at goal.

Conclusions  The SHAPE recommendations resulted in bidirectional reclassification of eligibility for lipid-lowering therapy in subjects aged 30 to 65 years. While broad implementation of these recommendations would modestly increase cholesterol-lowering drug use in this age range, the magnitude of the increase depends on whether standard or optional LDL-C goals are targeted.

Author Affiliations: Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas.

RELATED ARTICLE

Coronary Calcium Scoring and Cardiovascular Risk: The SHAPE of Things to Come
Mark J. Pletcher and Philip Greenland
Arch Intern Med. 2008;168(10):1027-1028.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Coronary Calcium Scoring and Cardiovascular Risk: The SHAPE of Things to Come
Pletcher and Greenland
Arch Intern Med 2008;168:1027-1028.
FULL TEXT